argenx SE · ARGX · FY2025 Q4 · Calendar Q2 2026
argenx: VYVGART growth meets a broader indication pipeline
The supplied analysis supports a constructive but conditional view: VYVGART demand, potential MG label expansions, new delivery formats and a broad FcRn pipeline provide multiple growth avenues, while regulatory, reimbursement, competitive and clinical-execution risks remain material.
Earnings scorecard
Reported versus consensusMarket reaction
prior-close to event-session closeAsk FN2 about ARGX FY2025 Q4
Transcript, numbers and history already loadedFree account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
The current analysis adds positive Phase III ADAPT OCULUS results and an ocular MG filing plan to the prior quarter's expansion framework. It also emphasizes the planned auto-injector, next-generation FcRn candidates and continued advancement of myositis, MMN and Graves programs.
Guidance delta
Maintained; the supplied analysis identifies no change in guidance sentiment.
Key takeaways
- Management described strong VYVGART growth and first annual operating profitability.
- Positive ADAPT OCULUS results create an ocular MG label-expansion opportunity.
- Seronegative MG and ocular MG are the clearest near-term expansion priorities.
- Delivery-format progress and a next-generation FcRn pipeline support the longer-term case, but approvals, reimbursement and competition remain key variables.
Management priorities
- Pursue ocular MG and seronegative MG regulatory milestones.
- Advance myositis, MMN and Graves programs alongside next-generation FcRn candidates.
- Maintain prefilled-syringe momentum and prepare the planned auto-injector.
Follow ARGX with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeCompany context
Snapshot as of publicationargenx SE, a biotechnology company established in Amsterdam, the Netherlands, in 2008, is dedicated to developing innovative therapies primarily for autoimmune diseases. The company's operations span across key global markets, including the United States, Japan, Europe, the Middle East, Africa, and China. Its leading investigational therapy is efgartigimod, which is being developed to address a broad range of conditions. These include generalized myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary Sjögren's syndrome, post-COVID postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, ANCA-associated vasculitis, and antibody-mediated rejection. Also noted in connection with its lead product efforts is ENHANZE SC. The company's extensive development pipeline features several other promising candidates.…
Historical context
All ARGX earningsHealthcare peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| DGX Quest Diagnostics Incorporated | FY2026 Q3 · Calendar Q4 2026 | +4.5% | +1.8% | Quest Diagnostics: growth broadens, but PAMA remains a headwind |
| MEDP Medpace Holdings, Inc. | FY2026 Q3 · Calendar Q4 2026 | +9.0% | -1.3% | Medpace: Record awards lift backlog as 2026 outlook improves |
| MOH Molina Healthcare, Inc. | FY2026 Q3 · Calendar Q4 2026 | +12.7% | +0.8% | Molina reaffirms 2026 outlook as Florida contract scales |
Latest beats and misses
Who reports nextBeat on EPS
- DECKFY2027 Q2 · October 22, 2026+13.4% EPS-0.2% move
- OMCFY2026 Q3 · October 22, 2026+2.2% EPS+2.6% move
- SSNCFY2026 Q3 · October 22, 2026+0.6% EPS+2.8% move
- BEFY2026 Q3 · October 22, 2026+36.0% EPS-8.7% move
- ROPFY2026 Q3 · October 22, 2026+1.7% EPS+9.7% move
- BPOPFY2026 Q3 · October 22, 2026+5.8% EPS-2.8% move
Missed on EPS
- SNAFY2026 Q3 · October 22, 2026-5.9% EPS-3.4% move
- SPOTFY2026 Q3 · October 22, 2026-11.6% EPS+11.1% move
- VRSNFY2026 Q3 · October 22, 2026-2.0% EPS-0.9% move
- HBANMFY2026 Q3 · October 22, 2026-5.3% EPS+0.5% move
- HBANPFY2026 Q3 · October 22, 2026-5.3% EPS0.0% move
- PCGFY2026 Q3 · October 22, 2026-0.8% EPS-1.3% move
Get the ARGX recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
- FN2 earnings calendar · 2026-07-26T00:37:12.209961+00:00
- Polygon adjusted daily market bars · 2026-10-23T14:50:42.423659+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-10-23T14:50:42.421943+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-10-23. For educational purposes only; not investment advice.